Case study of COVID 19 from August to end of December 2020 in Babylon, Iraq
DOI:
https://doi.org/10.22317/imj.v5i3.1078Keywords:
Case Reports, COVID-19, Babylon, IraqAbstract
Objectives: The aim of study is to study Case study of COVID 19 in Babylon Province in Iraq. Method: In January 2021 we started searching for the official source for the numbers of people infected with COVID19 within the borders of Babylon Governorate, where the Babylon Health Department was reviewed, and after that we were directed with official authorization to the Public Health Department in Babylon Governorate / Department of Communicable Diseases / Respiratory Diseases Unit (weekly periodic visit). Where the official numbers were obtained for the number of infected people and the number of deaths that occur due to complication with this infection, as well as the number of recovery cases from the date of 01/08/2020 to 01/01/2021. Results: related to the number of infected cases we see decrease the no. of infected with corona virus in Babylon Governorate from beginning the study to become lest at the end of 2020 with the significant decrease (P < 0.05) (The highest infected cases were notices in first month (1/8 – 31/8) while the lowest cases were seen in last month (1/12 – 31/12)) that may be due to: The main cause may be the most people may have gained herd immunity or population immunity, is the indirect protection from an infectious disease that happens when a population is have immunity developed through previous infection, that may refer to the end of first wave of this pandemic which start from the June. Conclusion: Knowing the pathogenesis of the virus and risk factors, increasing the experience of doctors and working cadres, increasing clinical capacity, providing specialized treatments, increasing the number of ICU beds, in addition to increasing the number of respiratory ventilators and increasing the number of tests.
References
2. Coronavirus AFD. update: FDA authorizes first diagnostic test using at-home collection of saliva specimens. 2020.
3. Hassan SM, Jawad MJ, Ahjel SW, Singh RB, Singh J, Awad SM, et al. The Nrf2 activator (DMF) and covid-19: is there a possible role? Med Arch. 2020;74(2):134.
4. Lam TT-Y, Jia N, Zhang Y-W, Shum MH-H, Jiang J-F, Zhu H-C, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature. 2020;583(7815):282–5.
5. Rashid ZZ, Othman SN, Samat MNA, Ali UK, Wong KK. Diagnostic performance of COVID-19 serology assays. Malays J Pathol. 2020;42(1):13–21.
6. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. Jama. 2020;323(18):1843–4.
7. McIntosh K, Hirsch MS, Bloom A. Coronavirus disease 2019 (COVID-19). UpToDate Hirsch MS Bloom. 2020;5(1).
8. Lin Y-J, Chou W-J, Chang Y-P, Yen C-F. Denial of Justification for Vaccination: Its Multiple Related Variables and Impacts on Intention to Get Vaccinated against COVID-19. Vaccines. 2021;9(8):822.
9. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig. 2020;40(6):511–8.
10. Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract. 2020;48(4):169–79.
11. Hossen MS, Barek MA, Jahan N, Islam MS. A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med. 2020;1–13.
12. Dergaa I, Abdelrahman H, Varma A, Yousfi N, Souissi A, Ghram A, et al. COVID-19 Vaccination, Herd Immunity and The Transition Toward Normalcy: Challenges with The Upcoming Sports Event. Ann Appl Sport Sci. :0.
13. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–4.
14. Garcia-Vidal C, Sanjuan G, Moreno-GarcÃa E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83–8.
15. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015–27.